Democrats Pressure Medicare Agency For More Information on Alzheimer’s Coverage

Two key House Democrats are pressing the Centers for Medicare and Medicaid Services (CMS) for more information about how Medicare plans to cover a new class of Alzheimer’s drug.

The agency last week detailed how Medicare beneficiaries enrolled in outpatient prescription medication coverage will be able to obtain the drugs once they are granted full approval from the Food and Drug Administration (FDA). The process involves patients and physicians participating in registries designed to track how the medicines perform in real-world settings.

But in a letter dated Monday, Reps. Anna Eshoo (Calif.), the ranking Democrat on the House Energy and Commerce’s health subcommittee, and subcommittee member Nanette Diaz Barragán (D-Calif.) said the agency “failed to answer basic questions” about how the registry would work.

Read the source article at thehill.com